BRIEF-Catalyst Pharmaceuticals updates on trial for patients with congenital myasthenic syndromes
December 08, 2016 at 08:40 AM EST
* "Continue to believe that we will report top-line results from this study in second half of 2017"
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.